Dr. Gouze is the scientific founder of Therachon following her seminal findings showing the therapeutic potential for achondroplasia of soluble FGFR3 decoys. She performed her post-doctoral training at Harvard Medical School, where she later became an Instructor in Orthopedic surgery in the Center for Molecular Orthopedics. Dr. Gouze was later appointed Assistant Professor at the University of Florida and since 2009 has been Team Leader at Inserm Nice, France. Dr. Gouze is an expert in novel therapeutics for musculoskeletal disorders, focusing her research program on achondroplasia, a rare genetic disease causing short stature. In 2013, researchers in Dr. Gouze’s lab published a seminal paper in Science Translational Medicine that showed a soluble decoy version of FGFR3 increased bone length and reduced complications associated with achondroplasia in mice that have the same genetic mutation as humans with achondroplasia. In 2014, Dr. Gouze founded Therachon with financial backing from Versant Ventures and Inserm Transfer Initiative to discover and develop innovative therapies for rare genetic conditions. Dr. Gouze currently serves as the Acting Head of Pharmacology at Therachon. Dr. Gouze holds a PhD in Molecular Pharmacology from the University Henri Poincare in Nancy.

  Pharmacology